pp-177 Tablets, enteric coated
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Prevention of norovirus gastroenteritis (GII.4 and GI.1 strains) in adults
Clinical stage: Phase 2b — safety and immunogenicity study ongoing
Modality: Biologic (recombinant adenovirus type 5 oral tablet vaccine; second-generation)
Mechanism / Target: Oral adenovirus vector expressing norovirus VP1 capsid protein — induces mucosal IgA in gut (critical for norovirus protection) and systemic IgG; T-cell responses
Route / form: Oral tablet (enteric-coated; room-temperature stable)
Differentiation: Only oral norovirus vaccine candidate; mucosal IgA induction matches route of infection; no cold chain required; 25× greater fecal IgA than first-generation; no injectable alternative exists
Manufacturer #39196
Clinical-stage vaccine company pioneering oral tablet vaccines using an adenovirus vector platform. Develops thermostable, room-temperature-stable oral vaccines to replace injectable immunisations. Wholly owned norovirus and COVID-19 oral vaccine programmes advancing in Phase 2.
None